Achieving durable glycaemic control to reduce the long-term
risk of diabetes-related morbidity and mortality remains a central therapeutic challenge in the management of patients with
type 2 diabetes. Drug therapy may fail, either initially or over
time [1], requiring treatment intensification [2]. Despite this,
many patients fail to achieve and/or maintain glycaemic targets
[3–6] for a variety of reasons that may include disease progression and therapy-, patient- or physician-related factors. Of
particular importance is poor patient adherence secondary to
actual and/or feared side effects of therapy, especially those of